MPT0B098 是一种微管抑制剂(Ki 为 0.8 μM,IC50 为 0.8 μM),可抑制微管蛋白聚合、阻断 HuR 核质转运以降低 HIF-1α mRNA 稳定性,抑制 HIF-1α、TGF-β/Smad、JAK2/STAT3、FAK/肌动蛋白细胞骨架信号通路,上调 SOCS3 以强化对 JAK2/STAT3 通路的抑制,并诱导凋亡 (apoptosis),可用于包括头颈部鳞状细胞癌与人非小细胞肺癌在内的多种恶性肿瘤研究。
产品编号: MS-S15742 CAS No.: 1254363-89-7 分子式: C20H18N2O3S 分子量: 366.44
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

MPT0B098 是一种微管抑制剂(Ki 为 0.8 μM,IC50 为 0.8 μM),可抑制微管蛋白聚合、阻断 HuR 核质转运以降低 HIF-1α mRNA 稳定性,抑制 HIF-1α、TGF-β/Smad、JAK2/STAT3、FAK/肌动蛋白细胞骨架信号通路,上调 SOCS3 以强化对 JAK2/STAT3 通路的抑制,并诱导凋亡 (apoptosis),可用于包括头颈部鳞状细胞癌与人非小细胞肺癌在内的多种恶性肿瘤研究。

生物实验数据

生物活性 MPT0B098 is a microtubule inhibitor (Ki = 0.8 μM, IC50 = 0.8 μM) that inhibits tubulin polymerization, blocks HuR nucleocytoplasmic transport to reduce HIF-1α mRNA stability, suppresses the HIF-1α, TGF-β/Smad, JAK2/STAT3, and FAK/actin cytoskeleton signaling pathways, upregulates SOCS3 to enhance inhibition of the JAK2/STAT3 pathway, and induces apoptosis, and it can be used for research on various malignant tumors, including head and neck squamous cell carcinoma and human non-small cell lung cancer.
IC50 & Target

microtubule

0.8 μM (IC50)

microtubule

0.8 μM (Ki)

HIF-1α

 

TGF-beta/Smad

 

JAK2

 

STAT3

 

体外研究
(In Vitro)

MPT0B098 抑制多种人癌细胞系增殖,包括 H460、A549、H1299、HONE-1、PC-3、KB、HT29 和 MKN-45 细胞,IC50 为 78-150 nM;而 HUVEC 细胞对 MPT0B098 相对不敏感,IC50 为 510 nM。
MPT0B098 抑制微管蛋白聚合,Ki 为 0.8 μM,IC50 为 0.8 μM。
MPT0B098 (0-1000 nM; 24 h) 在 A549 细胞中通过升高 cyclin B1 和 MPM2、改变 Cdc25C 和 Cdc2 磷酸化、增加 TUNEL 阳性细胞、促进 Bcl-2 磷酸化并诱导 PARP 裂解,诱导 G2/M 期阻滞和凋亡。
MPT0B098 (0.2-0.5 μM; 16 h) 抑制 VEGF 诱导的 HUVEC 管腔样结构形成。
MPT0B098 (0.25 μM; 24 h) 抑制 VEGF 诱导的 HUVEC 迁移,且不降低 HUVEC 活力。
MPT0B098 (0-2 μM; 18 h) 浓度依赖性降低 HUVEC 胞内 VEGF 蛋白与上清分泌量;0-0.9 μM MPT0B098 处理 18 h 可抑制缺氧 A549 细胞分泌 VEGF。
MPT0B098 (0-0.9 μM; 18 h) 在缺氧条件下降低 A549 细胞中 HIF-1α 蛋白和 mRNA 水平,降低 HIF-1α mRNA 稳定性,并减少 HuR 从细胞核向细胞质转位。
MPT0B098 (111-444 nM;72 h) 在常氧、缺氧条件下抑制 OEC-M1 细胞增殖,常氧下 IC50 为 222 nM,缺氧下 IC50 为 265 nM。
MPT0B098 (111-444 nM;18 h) 浓度依赖性下调缺氧 OEC-M1 细胞内 HIF-1α 蛋白,阻断缺氧诱发的 F-actin 细胞骨架重构,降低缺氧介导的 FAK 磷酸化,总 FAK 蛋白表达无明显变化。
MPT0B098 (111-444 nM;18-36 h) 抑制缺氧 OEC-M1 细胞内 EMT 转录因子 Twist、SNAI2/Slug 的表达。
MPT0B098 (111-444 nM;36 h) 下调波形蛋白、N-cadherin,同时部分恢复 E-cadherin;抑制 TGF-β 蛋白表达与 Smad2/3 磷酸化,并降低缺氧 OEC-M1 细胞内 TGF-β1、TGF-β2 的 mRNA 水平。
MPT0B098 (111-444 nM;预处理 18 h + TGF-β 共刺激 18 h) 逆转 TGF-β 引发的缺氧 OEC-M1 细胞 Smad2/3 磷酸化。
MPT0B098 (111 nM;48 h) 逆转缺氧诱导的 OEC-M1 细胞间质形态改变。
MPT0B098 (111 nM;4-18 h) 时间依赖性抑制缺氧诱导的 OEC-M1 细胞迁移,且无明显细胞毒性。
MPT0B098 (0.12-0.5 μM;72 h) 浓度依赖性抑制多种口腔鳞状细胞癌细胞系 (OEC-M1、HSC-3、SCC-25、Tu183、DOK、YD-15) 活力,IC50 为 0.14-0.45 μM;正常 HOK 细胞敏感性较低,IC50 为 6.3 μM。
MPT0B098 (0.25 μM;0-60 min) 在 OEC-M1、HSC-3 细胞中诱导时间依赖性微管解聚,洗脱药物 60 min 后微管网络可部分恢复。
MPT0B098 (0.25、0.5 μM;12 h) 剂量依赖性引发 OEC-M1 细胞 G2/M 细胞周期阻滞与 Annexin V 阳性早期凋亡。MPT0B098 (0.12-1 μM;24 h) 上调口腔鳞状细胞癌细胞内活化 caspase-3、活化 PARP,同时下调抗凋亡蛋白 Bcl-2、Mcl-1、Pim-1、Survivin。
MPT0B098 (0.25 μM;15-240 min) 逐步降低 JAK2、TYK2、STAT3 的磷酸化水平与总蛋白表达,不改变 STAT3 mRNA 表达量。
MPT0B098 (0.25 μM;0-60 min) 选择性上调口腔鳞状细胞癌细胞内 SOCS2、SOCS3 蛋白表达,对 PIAS1/3、SOCS1 无上调作用。
MPT0B098 (0.25 μM) 联合 5 μM 顺铂 (MS-E94993) 或 5 μM 5-FU (HY-90006) 对 OEC-M1 细胞的增殖抑制、caspase-3 激活效果显著优。

Cell Cycle Analysis

Cell Line: A549
Concentration: 75, 150, 300, 450, 600 nM
Incubation Time: 24 h
Result: Induced G2/M phase arrest in a concentration-dependent manner.
Increased the G2/M phase population with a concomitant loss of the G0/G1 phase, increased cyclin B1 and MPM2 levels, shifted Cdc25C phosphorylation status, and increased hypophosphorylated Cdc2.

Apoptosis Analysis

Cell Line: A549
Concentration: 150, 300, 600 nM
Incubation Time: 24 h
Result: Increased TUNEL-positive apoptotic cells in a concentration-dependent manner.
Increased the TUNEL-positive population from 1% in control cells to 4.9%, 24.7% and 78.7% at 150 nM, 300 nM and 600 nM, respectively.
Induced Bcl-2 phosphorylation and PARP cleavage.

Cell Migration Assay

Cell Line: HUVEC
Concentration: 0.25 μM
Incubation Time: 24 h
Result: Inhibited VEGF-induced HUVEC migration without compromising HUVEC viability.

Apoptosis Analysis

Cell Line: A549
Concentration: 0.1, 0.3, 0.6, 0.9, 1.2 μM
Incubation Time: 18 h
Result: Reduced hypoxia-induced HIF-1α protein expression in a concentration-dependent manner.

Real Time qPCR

Cell Line: A549
Concentration: 0.3, 0.6, 0.9 μM
Incubation Time: 24 h
Result: Reduced HIF-1α mRNA levels under hypoxic conditions, whereas colchicine did not reduce HIF-1α mRNA levels under the same experimental condition.

Immunofluorescence

Cell Line: A549
Concentration: 600 nM
Incubation Time: 6, 12, 18 h
Result: Reduced cytoplasmic HuR distribution and decreased HIF-1α expression under hypoxic conditions.

Cell Proliferation Assay

Cell Line: OEC-M1 under normoxic /hypoxic conditions
Concentration: 111, 222, 444 nM
Incubation Time: 72 h
Result: Inhibited OEC-M1 cell proliferation under normoxic and hypoxic conditions, and exerted weaker hypoxia-induced drug resistance.

Western Blot Analysis

Cell Line: OEC-M1
Concentration: 111, 222, 444 nM
Incubation Time: 18 h under hypoxia; 36 h under hypoxia; 18 h drug pretreatment + subsequent 18 h TGF-β co-stimulation under hypoxia
Result: After 18 h hypoxic treatment, dose-dependently downregulated HIF-1α protein, blocked hypoxia-triggered F-actin cytoskeleton rearrangement and reduced hypoxia-induced FAK phosphorylation without changing total FAK protein levels.
After 18 h and 36 h hypoxic treatment respectively, suppressed EMT transcription factors Twist and SNAI2/Slug.
After 36 h hypoxic treatment, downregulated mesenchymal markers vimentin and N-cadherin, partially restored epithelial marker E-cadherin, decreased TGF-β protein expression and inhibited Smad2/3 phosphorylation.
After 18 h hypoxic drug pretreatment followed by another 18 h TGF-β co-stimulation under hypoxia, reversed TGF-β-triggered Smad2/3 phosphorylation in hypoxic OEC-M1 cells.

Real Time qPCR

Cell Line: OEC-M1 under hypoxic conditions
Concentration: 111, 222, 444 nM
Incubation Time: 36 h
Result: Decreased mRNA transcription levels of TGF-β1 and TGF-β2 in hypoxic OEC-M1 cells.

Immunofluorescence

Cell Line: OEC-M1 under hypoxic conditions
Concentration: 111nM
Incubation Time: 48 h
Result: Reversed hypoxia-induced mesenchymal fibroblast-like morphological transformation of OEC-M1 cells.

Cell Migration Assay

Cell Line: OEC-M1 under hypoxic conditions
Concentration: 4 h, 6 h, 8 h, 18 h
Incubation Time: 48 h
Result: Time-dependently inhibited hypoxia-induced OEC-M1 cell migration without obvious cytotoxicity, and its anti-migration activity was superior.

Cell Cycle Analysis

Cell Line: OEC-M1
Concentration: 0.25 μM, 0.5 μM
Incubation Time: 12 h
Result: Induced dose-dependent G2/M phase cell cycle arrest in OEC-M1 cells.

Apoptosis Analysis

Cell Line: OEC-M1, HSC-3, DOK, YD-15
Concentration: 0.12 μM, 0.25 μM, 0.5 μM, 1 mM
Incubation Time: 24 h
Result: Induced concentration-dependent cell apoptosis.
Elevated activated caspase-3 and cleaved PARP.
Downregulated anti-apoptotic proteins including Bcl-2, Mcl-1, Pim-1 and Survivin.

Western Blot Analysis

Cell Line: OEC-M1, HSC-3
Concentration: 0.25 μM
Incubation Time: 15 min, 30 min, 60 min, 120 min, 240 min
Result: Time-dependently decreased phosphorylation and total protein levels of JAK2, TYK2 and STAT3 without altering STAT3 MRNA.
Selectively upregulated SOCS2 and SOCS3 protein while SOCS1, PIAS1 and PIAS3 kept stable expression.
Prolonged the half-life of SOCS3 protein, strengthened the binding between SOCS3 and JAK2/TYK2, and promoted the ubiquitination and degradation of JAK2 and TYK2.

Cell Cytotoxicity Assay

...(内容过长已截断)
Cell Line: OEC-M1
Concentration: 0.25 μM
体内研究
(In Vivo)

MPT0B098 (25, 50 mg/kg; 腹腔注射; 每日一次; 连续 5 天) 在 A549 人非小细胞肺癌移植瘤裸鼠模型中抑制肿瘤生长并降低微血管密度。

Animal Model: Five-week-old nude mice subcutaneously implanted with A549 cells (2 × 106 cells) into the right flank region
Dosage: 25, 50 mg/kg
Administration: Intraperitoneal injection (i.p.); once daily; for 5 consecutive days
Result: Intraperitoneal injection (i.p.); once daily; for 5 consecutive days Delayed A549 xenograft tumor growth in a dose-dependent manner.
Reduced CD31-positive microvessel density in tumor specimens.
Was well tolerated up to 50 mg/kg.
Caused no obvious signs of toxicity in drug-treated mice.
Maintained body weight loss within 15% in all treatment groups.

化学信息

分子量 366.44
分子式 C20H18N2O3S
CAS No. 1254363-89-7

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础

  • 客服

    2851296953

    18923798467

    微信洽谈